CPIC 2026丨专场对话：借力中国创新，加速全球药物研发进程

当前，中国已迅速崛起为世界级生物医药创新高地，在细胞与基因治疗、ADC、TCE、AI药物发现等前沿领域持续突破，不断推出全球首创、同类最优的创新疗法与突破性技术平台，创新势能强劲，发展势头瞩目。

为进一步凝聚全球产业智慧，推动中国创新与全球研发深度融合，由同写意主办的首届“大国新药”全球会议（CPIC2026），将于2026年7月22-24日在国家会展中心（上海）举办。

CPIC立足中国生物医药创新力量，深度链接全球研发、产业与资本生态，打造“中国创新—全球转化—上海交易”的国际化合作平台，以“领航中国新药，赋能全球创新”为愿景，助力中国创新药走向世界，推动全球药物研发与健康产业高质量发展。

本届大会期间将特别设置“借力中国创新，加速全球药物研发进程”专场研讨，汇聚东西方药物研发、战略合作与投资领域顶尖嘉宾，共同探讨中国生物医药创新浪潮如何重塑全球药物研发格局，为企业管线布局、投资组合优化与患者价值提升提供前沿思路。

本专场面向迈向全球化的中国创新企业、寻求差异化机遇的海外投资者，是把握全球新药研发合作趋势、链接高端资源、推动创新成果高效转化的核心交流平台。

无论你是准备走向全球的中国创新者，还是寻求差异化机遇的西方投资者，这场对话都是你不容错过的。

China has emerged as a world-class biomedical innovation hub—producing best-in-class and first-in-class therapies, breakthrough pipelines across disease areas, and cutting-edge platforms in cell and gene therapy, ADCs, TCEs, and AI-driven drug discovery. The science is here. The momentum is undeniable.

To further gather global insights and deepen integration between China’s innovation and global R&D, The 1st China Pharmaceutical Innovation Conference (CPIC 2026), hosted by TONACEA, will be held on July 22–24, 2026 at the National Exhibition and Convention Center (Shanghai).

Rooted in China’s biomedical innovation power, CPIC 2026 deeply connects global R&D, industrial and capital ecosystems to build an international cooperation platform featuring “Innovation in China - Translation Globally - Deal-Making in Shanghai”. With the vision of “Leading China’s New Drugs, Empowering Global Innovation”, CPIC 2026 empowers Chinese innovative drugs to go global and promotes high-quality development of global drug R&D and healthcare industry.

The conference will feature a distinguished panel session. This panel brings together top guests from global drug development, strategic partnership and investment sectors. It will explore how China’s biomedical innovation wave is reshaping the global drug development landscape, and provide forward-looking insights for pipeline optimization, portfolio strategy and patient value enhancement.

This panel brings together drug developers, strategic partners, and investors from both East and West to explore how China's biomedical rise is reshaping the global drug development landscape—and what it means for your pipeline, your portfolio, and your patients.

Whether you are a Chinese innovator ready to go global or a Western investor seeking differentiated opportunities, this is the conversation you cannot afford to miss.